{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:34:37Z","timestamp":1774380877446,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dendritic cells play a critical role in immunity. Fms-related tyrosine kinase 3 ligand (FLT3L) is a cytokine that can promote the expansion and differentiation of bone marrow dendritic cells (DC) progenitors. RO7497987 (FLT3L-Fc) is a novel FLT3 agonist developed to extend the half-life of FLT3L and induce expansion of peripheral blood DC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Phase Ia trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7497987 in healthy volunteers. Forty-four participants received RO7497987 as a single ascending dose (SAD, 0.7\u201370 mg) or multiple ascending doses (MAD, 7 or 21 mg, 21 days apart).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      RO7497987 was safe and well-tolerated at all doses. The most common treatment-related adverse events (AE) were Grade 1 myalgia, headache, and lymphadenopathy, all of which resolved spontaneously. There were no Grade \u2265\u00a03 AEs, serious AEs, or dose-limiting adverse events. Pharmacokinetic analysis showed dose-dependent increases in FLT3L-Fc C\n                      <jats:sub>max<\/jats:sub>\n                      and AUC\n                      <jats:sub>inf<\/jats:sub>\n                      with no accumulation in the MAD cohorts. RO7497987 administration resulted in dose-dependent expansion of monocytes, as well as expansion of all major DC subsets, including conventional and plasmacytoid DC, which was sustained with multiple doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings aid the design of dosing regimens of RO7497987 as an immunomodulatory agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.isrctn.com\/ISRCTN92655801<\/jats:uri>\n                      , identifier ISRCTN92655801.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1784546","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:17:09Z","timestamp":1774369029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers"],"prefix":"10.3389","volume":"17","author":[{"given":"Anthony J.","family":"Iacovelli","sequence":"first","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shomyseh","family":"Sanjabi","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharareh","family":"Monemi","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assaf","family":"Amitai","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie","family":"Decalf","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Moussion","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Z.","family":"Liao","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautham K.","family":"Rao","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Getz","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","article-title":"Decisions about dendritic cells: past, present, and future","volume":"30","author":"Steinman","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03101","article-title":"Immune cell composition in human non-small cell lung cancer","volume":"9","author":"Stankovic","year":"2019","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/cancers11040521","article-title":"Dendritic cells and cancer: from biology to therapeutic intervention","volume":"11","author":"Wylie","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.2.459","article-title":"STK-1, the human homolog of Flk-2\/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells","volume":"91","author":"Small","year":"1994","journal-title":"Proc Natl Acad Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1404-02","article-title":"Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer","volume":"10","author":"Higano","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00220-5","article-title":"Upregulation of Flt3 expression within the bone marrow Lin\u2013Sca1+c-kit+ stem cell compartment is accompanied by loss of self-renewal capacity","volume":"15","author":"Adolfsson","year":"2001","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.261562798","article-title":"Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells","volume":"98","author":"Christensen","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089482","article-title":"In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development","volume":"99","author":"Tsapogas","year":"2014","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.5.1953","article-title":"Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified","volume":"184","author":"Maraskovsky","year":"1996","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.878","article-title":"In vivo generation of human dendritic cell subsets by Flt3 ligand","volume":"96","author":"Maraskovsky","year":"2000","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.1.566","article-title":"Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo","volume":"165","author":"Pulendran","year":"2000","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200105000-00004","article-title":"Role of hematopoietic growth factors\/flt3 ligand in expansion and regulation of dendritic cells","volume":"8","author":"McKenna","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2122","article-title":"Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice","volume":"99","author":"O'Keeffe","year":"2002","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030323","article-title":"Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo","volume":"198","author":"Karsunky","year":"2003","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.74","article-title":"Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers","volume":"50","author":"Anandasabapathy","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The role of type 1 conventional dendritic cells in cancer immunity","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03059","article-title":"Dendritic cells and CD8 T cell immunity in tumor microenvironment","volume":"9","author":"Fu","year":"2018","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2019.07.004","article-title":"Dendritic cell subsets and locations","volume":"348","author":"Balan","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40425-019-0565-5","article-title":"Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen","volume":"7","author":"Wculek","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3727\/096504017X14841698396865","article-title":"CD103+ cell growth factor Flt3L enhances the efficacy of immune checkpoint blockades in murine glioblastoma model","volume":"26","author":"Miao","year":"2018","journal-title":"Oncol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19192-z","article-title":"Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s","volume":"11","author":"Oba","year":"2020","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00143-y","article-title":"Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets","volume":"1","author":"Bhardwaj","year":"2020","journal-title":"Nat Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e70011","DOI":"10.1111\/cts.70011","article-title":"Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants","volume":"17","author":"Dauki","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2808","article-title":"Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc fusion protein, in patients with advanced solid tumors","volume":"30","author":"Tolcher","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105822","DOI":"10.1016\/j.ebiom.2025.105822","article-title":"Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations","volume":"118","author":"Decalf","year":"2025","journal-title":"EBioMedicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/pharmaceutics16050660","article-title":"A minimal PBPK\/PD model with expansion-enhanced target-mediated drug disposition to support a first-in-human clinical study design for a FLT3L-fc molecule","volume":"16","author":"Hosseini","year":"2024","journal-title":"Pharmaceutics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"116837","DOI":"10.1016\/j.taap.2024.116837","article-title":"Nonclinical pharmacokinetics, pharmacodynamics and safety assessment of a FLT3L-Fc molecule for cancer immunotherapy","volume":"483","author":"Wu","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03681-0","article-title":"FLT3 targeting in the modern era: from clonal selection to combination therapies","volume":"120","author":"Kennedy","year":"2024","journal-title":"Int J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0460","article-title":"FLT3 agonists and secondary hematopoietic Malignancies: A potential class effect","volume":"30","author":"Raeder","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9618","article-title":"FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer","volume":"38","author":"Ohri","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1784546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:17:11Z","timestamp":1774369031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1784546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1784546"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1784546","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"1784546"}}